Abstract:Shikonin has previously been reported to function as a potent anti-cancer drug that induces cell apoptosis via diverse pathways. To optimize the effectiveness of its pro-apoptotic functions, shikonin was chosen as the best compound for obtaining shikonin ester derivatives (3a–3n) because it possesses an ester group on the side chain hydroxyl position, and the biological activity was evaluated as a potent anti-proliferating inhibitor for many cancer cell lines. Among these compounds, compound 3j exhibited better anti-cancer activities against human hepatocellular carcinoma cell line (HepG2) with an IC50 value of 0.759 μM which was better than that of shikonin which was 1.288 μM. The flow cytometry results showed that compound 3j inhibited the cell growth and caused the cell cycle to be arrested at the G2/M phase. Meanwhile, obvious apoptosis induced by 3j was observed using the Annexin V combined with propidium iodide assay, showing that 3j induced apoptosis of HepG2 cells in a dose and time dependent manner. To investigate the underlying mechanism in the process of apoptosis induced by 3j, the western blot technique was used and the cleavage of caspase-9 was observed but not that of caspase-8. Furthermore, the elevated expression of the p53 protein was positively correlated with the decreased Bcl-2 protein levels and increased Bax protein and the cytochrome C levels. This indicated that the mitochondrial apoptosis pathway directed by p53 responded in the process of apoptosis was induced by 3j. Based on these data, we conclude that compound 3j has the best anti-proliferating and pro-apoptotic effect among the 14 newly synthesized compounds, and it could be a potent candidate for cancer therapy.

Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach.

Design, Synthesis and Anticancer Activity of Shikonin and Alkannin Derivatives with Different Substituents on the Naphthazarin Scaffold

Advance in Anti-tumor Mechanisms of Shikonin, Alkannin and Their Derivatives.

Synthesis and Evaluation of Novel Alkannin and Shikonin Oxime Derivatives As Potent Antitumor Agents.

Design, synthesis and mechanism of novel shikonin derivatives as potent anticancer agents

Design, Synthesis and Biological Evaluation of Cinnamic Acyl Shikonin Derivatives

Design, Synthesis and Biological Evaluation of Anilide (dicarboxylic Acid) Shikonin Esters As Antitumor Agents Through Targeting PI3K/Akt/mTOR Signaling Pathway

Design, Syntheses and Biological Evaluation of Natural Product Aiphanol Derivatives and Analogues: Discovery of Potent Anticancer Agents

Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.

Synthesis of Aryl Dihydrothiazol Acyl Shikonin Ester Derivatives As Anticancer Agents Through Microtubule Stabilization.

Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.

Design, synthesis and biological evaluation of marine naphthoquinone-naphthol derivatives as potential anticancer agents

DMAKO-20 As a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.

Design and Synthesis of Fluoroacylshikonin As an Anticancer Agent.

Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment

Design and Synthesis of Biotinylated Dimethylation of Alkannin Oxime Derivatives

Synthesis and Biological Evaluation of Novel Shikonin Ester Derivatives As Potential Anti-Cancer Agents

Design, Synthesis and Anticancer Activity of Naphthoquinone Derivatives.

Chemical and biological studies of nakiterpiosin and nakiterpiosinone.

Semi-synthesis and Antitumor Activity of 6-Isomers of 5, 8-O-dimethyl Acylshikonin Derivatives

Design and Synthesis of New 2-Arylnaphthyridin-4-ones As Potent Antitumor Agents Targeting Tumorigenic Cell Lines